Accuray Incorporated (ARAY)

Accuray's stock has decreased significantly over the past six months. Key events include announcing convertible notes exchange and refinancing of existing credit facilities in June 2025. In August 2025, the company reported its fourth quarter and fiscal 2025 financial results, with net revenue decreasing by 5% and the stock price decreasing as Q4 earnings missed estimates. In October 2025, Accuray announced accelerated transformation efforts, including the appointment of a new CEO. In November 2025, Accuray reported its fiscal 2026 first-quarter financial results, with an EPS miss but positive investor response to revenue performance and strategic initiatives. Insider buying activity was also noted.

Accuray has observed seasonality in its demand, with higher operating expenses in the fourth quarter, indicating fluctuations in business activities and associated costs throughout the fiscal year.

Accuray, Inc. is a radiation therapy company specializing in advanced radiation oncology systems. Its core mission is to provide personalized treatment solutions. Major products include the CyberKnife and TomoTherapy platforms, Accuray Precision Treatment Planning System, iDMS Data Management System, Accuray Helix, and Accuray Stellar Solution. Accuray also generates revenue from long-term service contracts, which constituted approximately 50.8% of total revenue in fiscal year 2024.

Accuray is headquartered in Madison, Wisconsin, and maintains other U.S. locations in Santa Clara and Sunnyvale, CA. Its platforms are installed in healthcare centers in approximately 50 countries, with regional offices in Switzerland, Japan, China, and Hong Kong. Accuray sells its products directly to customers and through sales agents and group purchasing organizations in the U.S. Internationally, sales are conducted directly and through distributors and sales agents. The company has manufacturing facilities in Madison, WI, and Chengdu, China.

Accuray's brand reputation stands at 3.8/5 across four platforms, with specific platform ratings including 4.3/5 on Google, 3.6/5 on Indeed, and 3.8/5 on Glassdoor. In 2022, Accuray was recognized by the IMV ServiceTrak report for achieving "Best in Service in Radiation Oncology". The company emphasizes its commitment to innovation, patient focus, accountability, collaboration, and quality in its core values. No specific negative events significantly impacting Accuray's brand reputation in the past year were prominently found.

Institutional investors hold a significant portion of Accuray's shares, including TCW Group Inc., BlackRock, Inc., and The Vanguard Group, Inc. As of September 30, 2025, BlackRock, Inc. held 8,767,301 shares, and Vanguard Group Inc. held 5,476,677 shares. Institutional investors collectively hold approximately 58.7% of the company's shares. Insider buying has been observed, with insiders buying more shares than they have sold.